Navigation Links
Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy

BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today announced its 2010 growth strategy.

    Lotus's priorities for the balance of 2009 are
    1) deciding what the Company needs to do for its most valuable customers
       and continuing on its efforts, and
    2) identifying new product and market demand, and
    3) preparing for the construction of a new office building on the ground
       of its existing plant so that operational efficiency could be achieved
       by moving the separate units of sales, production and R&D bases into
       one single location.  This has been made possible because the
       government approved the zoning right of Lotus's property in Beijing to
       upgrade to industrial use in June of 2009.  Lotus is permitted to build
       gross floor areas of 20,353 square meters in four-nine floors above the
       ground and one floor underground.

Dr. Zhong Yi Liu, Chairman and CEO of Lotus commented, "Based on the past two years of business expansion, we currently believe that we will achieve our financial goals for the year 2009 and grow steady in the year of 2010." The Company's growth plan for the next year, includes, but is not limited to the following areas:

Expand Sales Network. Lotus currently plans to add 15-20 more distributors by the end of 2010 to its nation-wide sales channels. Lotus attends substantially every major drug expos in China. Lotus's sales representatives are experienced with medical education backgrounds, and are located in ten regional sales centers providing sales and post-sales services to its customers. Regional distributors come into contact with Lotus through words of mouth and public information.

Government hospitals have been Lotus's important direct sales channels. Any additional hospitals to increase the Company believes will have high entry barriers. Lotus plans to attempt to add new hospital channels in 2010.

Increase Quality Drugs Offering. Lotus's brand quality stems from its commitment to quality and efficacy of products. In case State Food and Drug Administration ("SFDA") is slow in approving any of the drugs in the pipeline, Lotus will attempt to produce drugs produced by third parties and sell them through its national sales force and network. By the end of 2010, Lotus currently intends to sell approximately 20 types of prescription drugs including its current 15 prescription drugs. Developing drugs to treat cardio-cerebrovascular, asthma and diabetes diseases remain the strategic focus in Lotus's pipeline development.

Geographic and Production Expansion. Production expansion is a part of Lotus's long term plan to tailor to its demand from drugs development. Lotus currently intends to start building the main body of the new facility in Inner Mongolia in 2010 subject to obtaining financing and self-generated capital. As part of the plan, a wholesales center would be established in Inner Mongolia to facilitate the growing market demand for pharmaceutical drugs in Inner Mongolia and five Northwestern provinces.

About Lotus Pharmaceuticals, Inc. ( )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus's current drug development pipeline is focused on the treatment of cardio-cerebrovascular disease, asthma, and diabetes.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the SFDA and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868

SOURCE Lotus Pharmaceuticals, Inc.

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
4. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
11. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Post Your Comments:
(Date:12/1/2015)... Va. , Dec. 1, 2015 Oxford ... senior debt to life sciences and healthcare services companies, ... secured term loan with MDRejuvena, Inc. ("the Company"). Proceeds ... and continued development of the Company,s Rejuvaphyl™ and daily ... Rejuvaphyl is the MDRejuvena brand of high potency ...
(Date:12/1/2015)... Clara, CA (PRWEB) , ... December 01, 2015 ... ... Force Microscopy (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance ... easily integratesthe power of SICM to an AFM. , Park SICM benefits virtually ...
(Date:12/1/2015)... 1, 2015 Cepheid (Nasdaq: CPHD ) ... the Piper Jaffray Healthcare Conference in New ... is reaffirming its outlook for the fourth quarter of ... to discussing longer term business model expectations. ...  "We continue to be the fastest growing company of ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
Breaking Biology News(10 mins):